In a recent report, Informa Intelligence’s Biomedtracker highlighted various products that are anticipated to enter the US market in 2020 for the first time or in new indications. These therapies represent novel drug classes, large market opportunities and treatments that are predicted to heavily impact the current standard of care for certain indications.
Overall, Biomedtracker believes that more than 50 candidate medicines, across 15 broad therapeutic categories and involving more than 60 companies,...